Novo Nordisk tapped Maziar Mike Doustdar, its head of international operations, as its new chief executive officer and ...

Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a ...

A drug from Fulcrum Therapeutics showed promise in a sickle cell study, raising the possibility that a pill could be an ...

Novo Nordisk announced company veteran Maziar Mike Doustdar as its next CEO, as the firm struggles to regain its dominance in ...

NIH plans to shrink the share of grant applications it will award for the remainder of the fiscal year, in some cases by more ...

Researchers are turning to a new approach for early cancer detection, making use of nanoscale biological structures called ...

Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and ...

Improving how the FDA disseminates already-public information about approved drugs may be unsexy, but it would be a big step ...

WASHINGTON — President Trump’s tariffs on pharmaceuticals coming from the European Union will be set at 15% and will not go ...

Kennedy and advocates have very different views on how his tenure impacts the community of Americans with disabilities.

The FDA said it was clearing the way for Sarepta Therapeutics to resume shipments of its gene therapy for Duchenne muscular ...

There are nearly 11 million people in America who are older and extremely destitute — to the point where they qualify for a ...